AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma
University of Texas MD Anderson Cancer CenterThe CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023.